|
Check Us Out!!! Sign Up Now For Our Free Newsletter!! BRGO,QSAP,XCEL,XMDC,MTVO,GETA
(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (OTCBB: BRGO) Bergio International, Inc., (PINKSHEETS: QASP) Quasar Aerospace Industries, Inc., (OTCBB: XCEL) Xcellink International Inc., (PINKSHEETS: XMDC) XTend Medical Corp., (OTCBB: MTVO) Montavo, Inc., (OTCBB: GETA) Genta Incorporated
www.StockMarketingInc.com
To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com
email us!! info@StockMarketingInc.com or call 1-866-583-8960
---------------------------
(OTCBB: BRGO - Bergio International, Inc.)
LATEST NEWS!!
Bergio Signs Letter of Intent to Acquire Famous Italian Designer Mario Panelli
FAIRFIELD, N.J., Nov 19, 2009 -- Bergio International, Inc. (OTC Bulletin Board: BRGO) announces today that it has entered into a deal to acquire famous Italian designer Mario Panelli.
Mario Panelli reported $1.5 million in inventory, $1.4 million in sales for 2008, with moderate earnings. Bergio will acquire the Company for a liquidated inventory cost of $1,250,000 in cash.
"Bergio is very excited to sign a Letter of Intent to acquire famous Italian designer Mario Panelli. Mario Panelli has been in business for over 40 years and is known internationally for his designs. This acquisition will give Bergio exposure into the international markets," stated Berge Abajian, CEO of Bergio International, Inc.
About Bergio International, Inc.
Bergio is entering into its 20th year of operations with boutique, upscale jewelry stores. It currently sells its jewelry to approximately 150 independent jewelry retailers across the United States. Bergio has spent millions in branding the Bergio brand through tradeshows, trade advertising, national advertising and billboard advertising since launching the line in 1995. Bergio has manufacturing control over its line as a result of having a manufacturing facility in New Jersey as well as subcontracts with facilities in Italy and Bangkok.
We have established Bergio International as a holding company for the purpose of acquiring well-established jewelry design and manufacturing firms who possess branded product lines.
Additionally, Bergio intends to acquire design and manufacturing firms throughout the United States and Europe. If and when they pursue any potential acquisition candidates, they intend to target the top 10% of the world's jewelry manufactures that have already created an identity and brand in the jewelry industry.
---------------------------
(PINKSHEETS: QASP - Quasar Aerospace Industries, Inc.)
LATEST NEWS!!
Quasar Aerospace Industries, Inc. Details the Terms of Its $350 Million Funding
JACKSONVILLE, FL, Nov 18, 2009 -- Quasar Aerospace Industries, Inc. (PINKSHEETS: QASP) today released additional details regarding the Company's recently announced primary funding of $350 million.
Mark Lundquist, a Philadelphia based attorney and Senior Vice President for Strategic Planning for Quasar Aerospace Industries, Inc., stated, "This primary funding instrument will provide a $350 million cash infusion into Quasar. Closing documents are being prepared and closing is scheduled for mid-December." The funds from the transaction will be transferred to Quasar's account as lump sum, upon the execution of the final documents. The funding transaction is structured as a loan, the proceeds of which originate as part of a $1 billion bond issued by Inver Finance Ltd., an Irish corporation.
The bonds, which are secured by $1.4 billion of life settlement policies on individuals over 72 years of age, bear interest at 6.5% with a ten-year term. Under the terms negotiated, interest does not begin accruing until the end of the third year. Additionally, no principal payments become due until the end of the tenth year. Upon maturity of the loan Quasar has three options for repayment: (1) an issuance of the Company's common stock equal to approximately 9% of the common stock outstanding as payment in full of the principal, (2) extend the loan for two successive five years terms, or (3) pay off the principal and any accrued and unpaid interest.
Dean Bradley, CEO of Quasar Aerospace Industries, Inc., commented, "The company continues to make significant strides in the progressive growth of operations. Inver Finance has provided our Company with a very flexible financial instrument that I believe will provide major long-term benefits for the Company's continued growth and success."
---------------------------
(OTCBB: XCEL - Xcellink International Inc.)
LATEST NEWS!!
Xcellink Sets Target Definition Study to US Military Specifications for Optimal Mobile Banking Security
Quality and Certification Levels to Comply With the Principles of Relevant US Military Specifications, Which Will Facilitate Integration of Xcellink Products Into Banking and Related High Security Businesses
LAS VEGAS, NV, Nov 19, 2009 -- Xcellink International Inc. (OTCBB: XCEL), a developer of patented mobile payments & banking platforms, announced today that it has set new Preliminary Target Definition Studies for the development of the Xcellink Patented technology.
These studies are the basis for generating specifications that comply with the United States Military's security definitions. By definition, the Xcellink software will be rated as secure as possible, meeting and exceeding published industry standards.
This will facilitate integration into existing banking and related high security businesses, thereby creating a value-added proposition as the company develops contractual relationships.
In a 2008 survey, 62 percent overall and 72 percent of people with incomes from $100,000 to $150,000 reported "enhanced security" an essential before they would begin to use a mobile P2P service. In another 2008 survey, 61 percent of people said that hackers obtaining their financial information was a primary concern, and 55 percent said the same for the possibility of fraudulent transfers. Xcellink's technology has been designed to respond to these concerns, providing a safe platform for consumers of all types.
A Company spokesperson noted, "Security has been a paramount issue on the Internet for some years now, and only now are mobile applications starting to be the targets of hackers. Our systems are being designed to thwart threats, and are being built for the emerging adoption of mobile banking applications globally." In addition, the documentation provides companies and other entities that will license Xcellink's technology with a base for development, and the specification for the Target Definition Study at a sufficient level to ensure their development work can be presented to subsequent customers at quality and certification levels that are generally in accordance with US Military Specification MIL-STD-499A/B for system engineering and similar industry accepted standards.
About Xcellink Xcellink International Inc. is a developer of advanced platform-independent customer-centric payment systems and methodologies. Xcellink's patented system has the technical ability to replace all credit, debit, charge and smart cards, providing all functions of order, warehousing, delivery and payment for all types of goods and services in a customer-centric manner that is more efficient, economical, and secure than systems operating today. Xcellink's unique process enables customers, rather than the merchant, to initiate, control and pay for all transactions, without the need for credit cards, in real-time anywhere, anytime, and at a fraction of the cost of current transactions. Please visit www.xcellink.com
---------------------------
(PINKSHEETS: XMDC - XTend Medical Corp.)
LATEST NEWS!!
XTend Medical Corporation (XMDC) Discusses Corporate Structure
SUN VALLEY, CA, Nov 19, 2009 -- XTend Medical (PINKSHEETS: XMDC), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, released the following statement regarding their corporate structure: "We've had several email inquiries as to the company's corporate structure regarding the press release issued on November 18th in regards to the upcoming asset purchase and merger with BioHarp. Our current authorized share structure will not change in order to effectuate this transaction. Our current capital reserves are also sufficient to consummate the asset purchase. We have began the process of converting preferred shares into common shares in order to insure the integrity of the company as we move forward to gain a listing on a higher exchange. There will be no need to alter our authorized shares whatsoever. In addition, the potential of the company in the future would justify us maintaining our current share structure with no plans to reverse the stock. Mr. Friedman and I feel strongly enough about the BioHarp that we will be utilizing our equity in the company to finalize any shares issued for the transaction. As for any delays perceived, it is my responsibility as CEO of XTend to insure the company has taken the proper steps to insure our valuation is at the greatest and we adhere to all U.S. and international tax laws and regulations. The company will finalize any merger opportunities, now and in the future, in the proper manner so as to insure the future of the company is not placed in harms way," stated Mr. Paul D. Lisenby, CEO of XTend Medical.
About XTend Medical XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis. For further information, please contact them at info@bioharpunius.com
---------------------------
(OTCBB: MTVO - Montavo, Inc.)
LATEST NEWS!!
Montavo Announces Engineering Development for the iPhone and iPod Touch to Coincide With the Release of Rev. 3.0
BELLEVUE, WASHINGTON, Nov 19, 2009) -- Montavo, Inc. (OTCBB: MTVO) is pleased to announce that the Company has prioritized engineering development efforts for mDealFinder(TM), the company's flagship mobile application, as well as the Montavo Mobile Advertising Platform (mMAP) for the Apple iPhone and Apple iPod Touch so the platform will be supported with the release of Rev. 3.0 planned for Q1 2010.
With over 100 million iPhone and iPod Touch downloaded applications each month via the App Store, the Apple platform has clearly set the standard for mobile applications.
Montavo recently announced an initiative to upgrade the overall user interface (UI) and user experience (UX) of both the mDealFinder(TM) application as well as mMAP suite of online tools for advertisers. These enhancements will also be incorporated into the iPhone and iPod Touch mDealFinder(TM) application which are focused on providing seamless, intuitive user interactions.
"We're very excited about our recent focus and prioritization of the development for the iPhone and iPod Touch mDealFinder(TM) application," said Brook Lang, CEO of Montavo. "With the rapidly growing footprint of both devices, we're looking forward to providing consumers with an innovative, intuitive, free application that will help them save significant dollars on everything from groceries to dress shoes to flat screen TVs in real-world store locations. Our ability to deliver mobile coupons, product information & launches, discounts, and savings opportunities to consumers by marrying their location with retailers that are offering the best deals on products or services they are looking to buy is unparalleled." About Montavo, Inc.
Montavo, Inc.'s mMAP is a mobile marketing platform that integrates client side mobile device software with a mobile advertising network solution and ad distribution ecosystem. Montavo offers its solution to consumer focused advertisers (manufacturers and retailers from national brands to SMBs), wireless carriers, mobile handset manufacturers and mobile OS providers, personal navigation device (PND) manufacturers, automotive manufacturers, and other tier-one suppliers as either a white-labeled mobile application or as the Montavo branded mDealFinder(TM).
Montavo's proprietary, patent-pending mobile advertising platform has been designed from the ground up to deliver the most relevant, location-based deals on products or services to consumers while providing rich real-time data and analytics on mobile ad campaign performance and ROI to advertisers that primarily sell their products in a brick and mortar setting.
---------------------------
(OTCBB: GETA - Genta Incorporated)
LATEST NEWS!!
Genasense(R) Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma
Data Presented at International Melanoma Conference in Berlin
BERKELEY HEIGHTS, N.J., Nov 20, 2009 -- --Results Follow Decision by Company to Continue Phase 3 AGENDA Trial for Overall Survival Genta Incorporated (OTCBB: GETA.OB) announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company's lead oncology product, Genasense(R) (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion. The data were featured this week in a presentation at the annual World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Berlin, Germany. Based on preclinical evidence of synergy, this study combined Genasense with temozolomide (Temodar(R); Schering Plough, Inc.), the most commonly used anticancer drug for melanoma, and Abraxane(R) (paclitaxel protein-bound particles for injectable suspension [albumen bound]; Abraxis Bioscience, Inc.). Previous results using a standard dose and schedule of Genasense (i.e., approximately 500 mg infused over 24 hours daily for 7 days) suggested this investigational combination was associated with clinical activity and good tolerability in 18 patients.
In the new schedule, Genasense was administered with the same chemotherapy as a brief IV infusion over 1-hour twice per week for 4 consecutive weeks at a dose of 900 mg. This schedule compresses approximately 48 hours of standard dosing into a brief 1-hour infusion.
To date, 10 patients with Stage IV metastatic melanoma have been accrued to this ongoing trial. Three patients achieved confirmed partial responses after the first 2 treatment cycles with current durations lasting from 24 to 40 weeks. One patient has maintained stable disease that has lasted 16 weeks, two patients have progressed, and four patients are too early to evaluate, having received only a single cycle. Only one episode (i.e., Grade 3 neutropenia) of any Grade 3-4 adverse event has been observed.
"With a preliminary disease control rate (defined as complete or partial responses plus stable disease lasting at least 3 months) of 67%, we view these data as very promising," said Dr. Loretta M. Itri, Genta's President, Pharmaceutical Development. "Temozolomide is the active metabolite of dacarbazine that has been used in our Phase 3 trial in patients with advanced melanoma. I am pleased to confirm that Genta will continue the Phase 3, randomized, double-blind AGENDA trial in order to determine overall survival in that study. Finally, taxanes are being increasingly used in patients with metastatic melanoma. We intend to initiate a Phase 2 study of our proprietary oral taxane, tesetaxel, in advanced melanoma. We hope our comprehensive approach with these new medicines may improve the management of this devastating disease." About the AGENDA trial in advanced melanoma Genta has completed enrollment into AGENDA, a Phase 3, randomized, double-blind, placebo-controlled trial of Genasense in patients with advanced melanoma. Initial results did not show statistically significant differences in overall response or progression-free survival. The endpoints of durable response (complete or partial response lasting greater-than or equal to 6 months) and overall survival are too early to evaluate. An analysis for futility has been conducted for the survival endpoint, and the trial has passed that analysis. The Company has announced it plans to continue to follow patients on AGENDA in order to determine this endpoint.
About the World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers This international conference is organized annually by the European Association of Dermatologic Oncology (EADO), which is a co-leader of the AGENDA trial. The meeting offers melanoma clinicians and researchers from multidisciplinary melanoma/skin cancer centers an opportunity to interact, establish collaborations, and set an agenda for the further evolution of melanoma care and research. Genta is a Co-Sponsor of the EADO meeting.
About Melanoma Malignant melanoma is the most deadly form of skin cancer. The incidence of this disease is increasing by approximately 4% annually in the U.S. Melanoma is the number one cause of cancer death in women aged 25 to 29. More information about melanoma can be accessed at the Melanoma Research Foundation: http://www.melanoma.org.
About Genasense Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta has pursued a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
About Genta Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genasense is being developed as an agent that may enhance the effectiveness of current anticancer therapy. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed oral formulations of the active ingredient in Ganite, which have completed preliminary clinical trials, as a potential treatment for diseases associated with accelerated bone loss. The Company is developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Genta intends to evaluate the clinical activity of tesetaxel in a range of human cancers. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
---------------------------
About StockMarketingInc.com
StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ InfoTech Spotlight's Homepage ]
|
